Literature DB >> 26140272

Bartter and Gitelman syndromes: Spectrum of clinical manifestations caused by different mutations.

Amar Al Shibli1, Hassib Narchi1.   

Abstract

Bartter and Gitelman syndromes (BS and GS) are inherited disorders resulting in defects in renal tubular handling of sodium, potassium and chloride. Previously considered as genotypic and phenotypic heterogeneous diseases, recent evidence suggests that they constitute a spectrum of disease caused by different genetic mutations with the molecular defects of chloride reabsorption originating at different sites of the nephron in each condition. Although they share some characteristic metabolic abnormalities such as hypokalemia, metabolic alkalosis, hyperplasia of the juxtaglomerular apparatus with hyperreninemia, hyperaldosteronism, the clinical and laboratory manifestations may not always allow distinction between them. Diuretics tests, measuring the changes in urinary fractional excretion of chloride from baseline after administration of either hydrochlorothiazide or furosemide show very little change (< 2.3%) in the fractional excretion of chloride from baseline in GS when compared with BS, except when BS is associated with KCNJ1 mutations where a good response to both diuretics exists. The diuretic test is not recommended for infants or young children with suspected BS because of a higher risk of volume depletion in such children. Clinical symptoms and biochemical markers of GS and classic form of BS (type III) may overlap and thus genetic analysis may specify the real cause of symptoms. However, although genetic analysis is available, its use remains limited because of limited availability, large gene dimensions, lack of hot-spot mutations, heavy workup time and costs involved. Furthermore, considerable overlap exists between the different genotypes and phenotypes. Although BS and GS usually have distinct presentations and are associated with specific gene mutations, there remains considerable overlap between their phenotypes and genotypes. Thus, they are better described as a spectrum of clinical manifestations caused by different gene mutations.

Entities:  

Keywords:  Bartter syndrome; Chloride; Genetics; Gitelman syndrome; Magnesium; Metabolic alkalosis; Potassium

Year:  2015        PMID: 26140272      PMCID: PMC4482822          DOI: 10.5662/wjm.v5.i2.55

Source DB:  PubMed          Journal:  World J Methodol        ISSN: 2222-0682


  41 in total

Review 1.  Gitelman's syndrome: a pathophysiological and clinical update.

Authors:  Farid Nakhoul; Nakhoul Nakhoul; Evgenia Dorman; Liron Berger; Karl Skorecki; Daniella Magen
Journal:  Endocrine       Date:  2011-11-15       Impact factor: 3.633

2.  Spectrum of mutations in Gitelman syndrome.

Authors:  Rosa Vargas-Poussou; Karin Dahan; Diana Kahila; Annabelle Venisse; Eva Riveira-Munoz; Huguette Debaix; Bernard Grisart; Franck Bridoux; Robert Unwin; Bruno Moulin; Jean-Philippe Haymann; Marie-Christine Vantyghem; Claire Rigothier; Bertrand Dussol; Michel Godin; Hubert Nivet; Laurence Dubourg; Ivan Tack; Anne-Paule Gimenez-Roqueplo; Pascal Houillier; Anne Blanchard; Olivier Devuyst; Xavier Jeunemaitre
Journal:  J Am Soc Nephrol       Date:  2011-03-17       Impact factor: 10.121

3.  A novel mutation in the chloride channel gene, CLCNKB, as a cause of Gitelman and Bartter syndromes.

Authors:  Israel Zelikovic; Raymonde Szargel; Ali Hawash; Valentina Labay; Ihab Hatib; Nadine Cohen; Farid Nakhoul
Journal:  Kidney Int       Date:  2003-01       Impact factor: 10.612

4.  Autosomal dominant hypocalcemia with mild type 5 Bartter syndrome.

Authors:  Giuseppe Vezzoli; Teresa Arcidiacono; Vera Paloschi; Annalisa Terranegra; Rita Biasion; Giovanna Weber; Stefano Mora; Marie Louise Syren; Domenico Coviello; Daniele Cusi; Giuseppe Bianchi; Laura Soldati
Journal:  J Nephrol       Date:  2006 Jul-Aug       Impact factor: 3.902

Review 5.  Bartter syndrome: an overview.

Authors:  I Amirlak; K P Dawson
Journal:  QJM       Date:  2000-04

Review 6.  How Bartter's and Gitelman's syndromes, and Dent's disease have provided important insights into the function of three renal chloride channels: ClC-Ka/b and ClC-5.

Authors:  Marie Briet; Rosa Vargas-Poussou; Stephane Lourdel; Pascal Houillier; Anne Blanchard
Journal:  Nephron Physiol       Date:  2005-12-12

7.  Clinical presentation of genetically defined patients with hypokalemic salt-losing tubulopathies.

Authors:  Melanie Peters; Nikola Jeck; Stephan Reinalter; Andreas Leonhardt; Burkhard Tönshoff; G ünter Klaus G; Martin Konrad; Hannsjörg W Seyberth
Journal:  Am J Med       Date:  2002-02-15       Impact factor: 4.965

8.  A common sequence variation of the CLCNKB gene strongly activates ClC-Kb chloride channel activity.

Authors:  Nikola Jeck; Petra Waldegger; Jolanta Doroszewicz; Hannsjörg Seyberth; Siegfried Waldegger
Journal:  Kidney Int       Date:  2004-01       Impact factor: 10.612

9.  Endocochlear potential depends on Cl- channels: mechanism underlying deafness in Bartter syndrome IV.

Authors:  Gesa Rickheit; Hannes Maier; Nicola Strenzke; Corina E Andreescu; Chris I De Zeeuw; Adrian Muenscher; Anselm A Zdebik; Thomas J Jentsch
Journal:  EMBO J       Date:  2008-10-02       Impact factor: 11.598

10.  Functional characterization of a calcium-sensing receptor mutation in severe autosomal dominant hypocalcemia with a Bartter-like syndrome.

Authors:  Rosa Vargas-Poussou; Chunfa Huang; Philippe Hulin; Pascal Houillier; Xavier Jeunemaître; Michel Paillard; Gabrielle Planelles; Michèle Déchaux; R Tyler Miller; Corinne Antignac
Journal:  J Am Soc Nephrol       Date:  2002-09       Impact factor: 10.121

View more
  13 in total

1.  AP-2β/KCTD1 Control Distal Nephron Differentiation and Protect against Renal Fibrosis.

Authors:  Alexander G Marneros
Journal:  Dev Cell       Date:  2020-06-17       Impact factor: 12.270

2.  Is this a seizure?

Authors:  Giulio Franceschet; Marta Mazzucato; Simona Censi; Stefano Simmini; Marco Boscaro; Valentina Camozzi
Journal:  Clin Cases Miner Bone Metab       Date:  2017-05-30

3.  Geller Syndrome: A Rare Cause of Persistent Hypokalemia During Pregnancy.

Authors:  Naif Hindosh; Rand Hindosh; Bolanle Dada; Swomya Bal
Journal:  Cureus       Date:  2022-06-24

4.  Clinical and Genetic Characterization of Patients with Bartter and Gitelman Syndrome.

Authors:  Viviana Palazzo; Valentina Raglianti; Samuela Landini; Luigi Cirillo; Carmela Errichiello; Elisa Buti; Rosangela Artuso; Lucia Tiberi; Debora Vergani; Elia Dirupo; Paola Romagnani; Benedetta Mazzinghi; Francesca Becherucci
Journal:  Int J Mol Sci       Date:  2022-05-18       Impact factor: 6.208

5.  New SLC12A3 disease causative mutation of Gitelman's syndrome.

Authors:  Teresa Grillone; Miranda Menniti; Francesco Bombardiere; Marco Flavio Michele Vismara; Stefania Belviso; Fernanda Fabiani; Nicola Perrotti; Rodolfo Iuliano; Emma Colao
Journal:  World J Nephrol       Date:  2016-11-06

6.  Increased urinary prostaglandin E2 metabolite: A potential therapeutic target of Gitelman syndrome.

Authors:  Xiaoyan Peng; Lanping Jiang; Chen Chen; Yan Qin; Tao Yuan; Ou Wang; Xiaoping Xing; Xuemei Li; Min Nie; Limeng Chen
Journal:  PLoS One       Date:  2017-07-10       Impact factor: 3.240

Review 7.  Bartter syndrome: causes, diagnosis, and treatment.

Authors:  Tamara da Silva Cunha; Ita Pfeferman Heilberg
Journal:  Int J Nephrol Renovasc Dis       Date:  2018-11-09

Review 8.  Rare Renal Diseases Can Be Used as Tools to Investigate Common Kidney Disorders.

Authors:  Mariadelina Simeoni; Sara Damiano; Giovanna Capolongo; Francesco Trepiccione; Miriam Zacchia; Giorgio Fuiano; Giovambattista Capasso
Journal:  Kidney Dis (Basel)       Date:  2017-05-25

9.  Bartter Syndrome Type 3: Phenotype-Genotype Correlation and Favorable Response to Ibuprofen.

Authors:  Xuejun Yang; Gaofu Zhang; Mo Wang; Haiping Yang; Qiu Li
Journal:  Front Pediatr       Date:  2018-05-30       Impact factor: 3.418

10.  Splicing Characterization of CLCNKB Variants in Four Patients With Type III Bartter Syndrome.

Authors:  Chunli Wang; Yuan Han; Jiaran Zhou; Bixia Zheng; Wei Zhou; Huaying Bao; Zhanjun Jia; Aihua Zhang; Songming Huang; Guixia Ding; Fei Zhao
Journal:  Front Genet       Date:  2020-02-21       Impact factor: 4.599

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.